August 2019 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2017/18 Invitation to Tender dated 2 November 2017, and the 2018/19 Invitation to Tender dated 1 November 2018.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by:
- For new listings, by 4pm on the 12 September 2019 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
PHARMAC cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2017/18 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2021
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand |
Date of subsidy change |
Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
|
Norethisterone |
Tab 5 mg; |
$18.29 |
$18.29 |
Primolut N |
1 October 2019 |
1 January 2020 |
2. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand (Supplier) |
Date of listing |
Date of reference pricing of other listed brands |
Sole Subsidised Supply date |
Brand (Supplier) affected by reference pricing and delisting |
|---|---|---|---|---|---|---|---|---|
|
Ibuprofen |
Tab long-acting 800 mg; |
$7.99 |
$5.99 |
Ibuprofen SR BNM |
1 February 2020 |
1 April 2020 |
1 July 2020 |
Brufen SR |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Hospital supply brand |
DV |
Date subsidy change |
Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
|
Norethisterone |
Tab 5 mg; |
$18.29 |
$18.29 |
Primolut N |
1% |
1 October 2019 |
1 December 2019 |
4. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Hospital supply brand (Supplier) |
DV Limit |
Listing date |
Hospital Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Ibuprofen |
Tab long-acting 800 mg; |
$7.99 |
$5.99 |
Ibuprofen SR BNM |
1% |
1 February 2020 |
1 April 2020 |
Brufen SR |
2018/19 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2022
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
5. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand |
Date of subsidy change |
Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
|
Phenoxymethylpenicillin (Penicillin V) |
Grans for oral liq 125 mg per 5 ml; |
$1.48 |
$2.99 |
AFT |
1 October 2019 |
1 January 2020 |
|
Phenoxymethylpenicillin (Penicillin V) |
Grans for oral liq 250 mg per 5 ml; |
$1.58 |
$3.99 |
AFT |
1 October 2019 |
1 January 2020 |
|
Tamsulosin hydrochloride [current access] |
Cap 400 mcg; |
$11.25 |
$17.73 |
Tamsulosin-Rex |
1 October 2019 |
1 January 2020 |
6. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand (Supplier) |
Date of listing/subsidy change |
Sole Subsidised Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Calcium folinate |
Inj 10 mg per ml, 5 ml vial; |
$4.55 |
$7.28 |
Calcium Folinate Sandoz |
1 October 2019 |
1 March 2020 |
Calcium Folinate Ebewe inj 50 mg |
|
Chloramphenicol |
Eye oint 1%; |
$2.48 |
$1.55 |
Deva |
1 December 2019 |
1 May 2020 |
Chlorsig |
|
Enalapril maleate |
Tab 5 mg; |
$3.84 |
$1.82 |
Acetec |
1 January 2020 |
1 June 2020 |
Ethics Enalapril |
|
Enalapril maleate |
Tab 10 mg; |
$4.96 |
$2.02 |
Acetec |
1 January 2020 |
1 June 2020 |
Ethics Enalapril |
|
Enalapril maleate |
Tab 20 mg; |
$7.12 |
$2.42 |
Acetec |
1 January 2020 |
1 June 2020 |
Ethics Enalapril |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
7. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Hospital supply brand |
DV |
Date of subsidy change |
Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
|
Calcium folinate |
Inj 10 mg per ml, 5 ml vial; |
$4.55 |
$7.28 |
Calcium Folinate Sandoz |
1% |
1 October 2019 |
1 January 2020 |
|
Phenoxymethylpenicillin (Penicillin V) |
Grans for oral liq 125 mg per 5 ml; |
$1.48 |
$2.99 |
AFT |
1% |
1 October 2019 |
1 January 2020 |
|
Phenoxymethylpenicillin (Penicillin V) |
Grans for oral liq 250 mg per 5 ml; |
$1.58 |
$3.99 |
AFT |
1% |
1 October 2019 |
1 January 2020 |
|
Tamsulosin hydrochloride [current access] |
Cap 400 mcg; |
$11.25 |
$17.73 |
Tamsulosin-Rex |
1% |
1 October 2019 |
1 January 2020 |
8. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Hospital supply brand |
DV |
Date of listing/subsidy change |
Hospital Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Calcium folinate* |
Inj 10 mg per ml, 100 ml vial; |
$60.00 |
$72.00 |
Calcium Folinate Sandoz |
1% |
1 October 2019 |
1 March 2020 |
Calcium Folinate Ebewe |
|
Chloramphenicol |
Eye oint 1%; |
$2.48 |
$1.55 |
Deva |
1% |
1 December 2019 |
1 May 2020 |
Chlorsig |
|
Enalapril maleate |
Tab 5 mg; |
$3.84 |
$1.82 |
Acetec |
1% |
1 January 2020 |
1 June 2020 |
Ethics Enalapril |
|
Enalapril maleate |
Tab 10 mg; |
$4.96 |
$2.02 |
Acetec |
1% |
1 January 2020 |
1 June 2020 |
Ethics Enalapril |
|
Enalapril maleate |
Tab 20 mg; |
$7.12 |
$2.42 |
Acetec |
1% |
1 January 2020 |
1 June 2020 |
Ethics Enalapril |
|
*The price and subsidy of calcium folinate inj 1 mg for ECP (Baxter) will be maintained. |
||||||||
Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:
- the 2017/18 Invitation to Tender, dated 2 November 2017, and
- the 2018/19 Invitation to Tender, dated 1 November 2018
2017/18 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Bumetanide |
Tab 1 mg |
2018/19 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Adenosine |
Inj 3 mg per ml, 10 ml |
|
Doxorubicin |
Inj 50 mg |
|
Fluorouracil sodium |
Inj 50 mg per ml, 50 ml |
|
Levosimendan |
Inj 2.5 mg per ml, 5 ml |
|
Tamsulosin [widened access] |
Tab 400 mcg |
|
Zinc oxide |
Powder |
For products included in the 2017/18 and 2018/19 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.